We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
An SI Board Since December 2006
Posts SubjectMarks Bans
10 2 0
Emcee:  nigel bates Type:  Moderated
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
10Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rightnsaf8/8/2010
9Galapagos enters into global alliance with Janssen Pharmaceutica on rheumatoid nigel bates10/24/2007
8ProStrakan and Galapagos receive additional milestone payment in antibody collabnigel bates9/27/2007
7Galapagos announces achievement of milestones totaling €3.2 million in osteoarthnigel bates3/30/2007 Galapagos announces 2006 full year results Friday March 2, 2:09 ascaram(o)uche3/2/2007
5Rosenwald, trying to stick it to a new generation of biotech investors.scaram(o)uche2/1/2007
4Galapagos announces PPAR-delta commercial license agreement with Hillcrest Theranigel bates2/1/2007
3Galapagos reports 2006 financial update, drug discovery advancements and changesnigel bates1/12/2007
2Mechelen, Belgium; 3 January 2007 - Galapagos NV (Euronext & LSE: GLPG) annonigel bates1/3/2007
1Galapagos acquires ProSkelia from ProStrakan and raises €31 million Creates drugnigel bates12/22/2006
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):